Brief: Nuformix Says FDA Grants Orphan Drug Designation For Co's NXP002 In IPF
10/03/2026 07:52
March 10 (Reuters) - Nuformix PLC NFXN.L: NUFORMIX PLC - FDA GRANTS ORPHAN DRUG DESIGNATION FOR NUFORMIX'S NXP002 IN IDIOPATHIC PULMONARY FIBROSIS Source text: ID:nRSJ9473Va Further company coverage: NFXN.L ((Reuters.Briefs@thomsonreuters.com;))